Flotex-C

Flotex-C is a preclinical-stage sustained-release oral capsule formulation of a cannabinoid, developed by APIRx Pharma Sciences (also known as Apixir Pharma Sciences). The drug is designed to provide extended exposure to the active cannabinoid ingredient, potentially improving therapeutic outcomes and patient compliance for various unmet medical indications. As of early 2024, the specific cannabinoid molecule and the targeted clinical indications have not been publicly disclosed, and the product remains in the preclinical phase with patent applications pending. It is part of APIRx's broader portfolio of cannabinoid-based delivery systems intended for controlled release.